Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
Details : Xspray Pharma's lead product XS004 (dasatinib) is being evaluated in the late-stage clinical trial studies for treating patients suffering from chronic myeloid leukemia.
Brand Name : XS004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2024
Apotex Launches Generic Dasatinib Tablets in The U.S.
Details : Sprycel (dasatinib) is an oral film-coated tablet, a protein kinase inhibiting small molecule drug. It is indicated for the treatment of chronic myeloid leukemia.
Brand Name : Sprycel-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024
Details : Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.
Brand Name : Dasynoc
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 12, 2024
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Xspray Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).
Brand Name : Dasynoc
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 24, 2023
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Xspray Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Alembic Gets USFDA Nod for Cancer Treatment Drug
Details : Dasatinib Tablet is indicated for treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.
Brand Name : Dasatinib-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2022
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Xspray Pharma Reports Positive Results From a Study with Dasatinib During Omeprazole Treatment
Details : Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric p...
Brand Name : HyNap-Dasa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 30, 2020
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
